This case report describes a young male patient with recurrent abdominal pain persisting for more than 16 months. Clinical investigations showed signs of inflammation and pancytopenia. A diagnosis of paroxysmal nocturnal hemoglobinuria (PNH) was made 9 months after the onset of the abdominal pain, following endoscopic examinations that revealed evidence of a previously unknown hemorrhage. Regular monitoring indicated that the abdominal pain was associated with elevations in lactate dehydrogenase, C-reactive proteins, and D-dimer levels. The patient started treatment with the complement inhibitor eculizumab shortly after it was approved for use in Japanese PNH patients with hemolysis. Resolution of the abdominal pain and normalization of clinical parameters were noted within 3 weeks from treatment initiation. 1. Introduction Paroxysmal nocturnal hemoglobinuria (PNH) is a rare and progressive hematopoietic stem cell disorder in which hematopoietic cells are deficient in glycosylphosphatidylinositol (GPI), which leads to a lack of the complement inhibitor proteins CD55 and CD59 on the surface of blood cells. This results in the characteristic intravascular hemolysis of red blood cells, along with platelet activation and aggregation [1]. PNH is fatal in up to 35% of patients within 5 years of diagnosis and in up to 50% of patients within 10 to 15 years of diagnosis [2, 3], largely as the result of thrombosis. Patients with PNH have an approximately 62-fold greater risk of thrombosis compared with the general population [4] and an estimated 10.2-fold increase in mortality risk [3]. The liver, kidney, brain, and gut are common sites of thromboembolism, and up to 44% of patients with PNH will experience a clinically evident thrombosis [3, 5]. Although the etiology and symptoms of PNH are similar in Japanese/Asian and Western patients, it has been suggested that the clinical course of the disease may differ between the ethnic groups [6]. Here, we describe a Japanese patient who experienced extensive abdominal pain over a period of 16 months accompanied by pancytopenia, signs of inflammation, and thickening of the intestinal wall. 2. Case Study In May 2009, a 22-year-old male with no relevant personal or family medical history started experiencing lower abdominal pain lasting for several days with repeated periods of exacerbation and remission. In December 2009, the patient attended an outpatient department for detailed examination, as the abdominal pain had not resolved. Routine tests revealed pancytopenia, with a white blood cell (WBC) count of 2,400/μL (lower
References
[1]
I. C. Weitz, “Thrombosis in patients with paroxysmal nocturnal hemoglobinuria,” Seminars in Thrombosis and Hemostasis, vol. 37, no. 3, pp. 315–321, 2011.
[2]
P. Hillmen, S. M. Lewis, M. Bessler, L. Luzzatto, and J. V. Dacie, “Natural history of paroxysmal nocturnal hemoglobinuria,” New England Journal of Medicine, vol. 333, no. 19, pp. 1253–1258, 1995.
[3]
G. Socié, J.-Y. Mary, A. De Gramont et al., “Paroxysmal nocturnal haemoglobinuria: long-term follow-up and prognostic factors,” The Lancet, vol. 348, no. 9027, pp. 573–577, 1996.
[4]
K. McKeage, “Eculizumab: a review of its use in paroxysmal nocturnal haemoglobinuria,” Drugs, vol. 71, no. 17, pp. 2327–2345, 2011.
[5]
P. Hillmen, P. Muus, U. Dührsen et al., “Effect of the complement inhibitor eculizumab on thromboembolism in patients with paroxysmal nocturnal hemoglobinuria,” Blood, vol. 110, no. 12, pp. 4123–4128, 2007.
[6]
J.-I. Nishimura, Y. Kanakura, R. E. Ware et al., “Clinical course and flow cytometric analysis of paroxysmal nocturnal hemoglobinuria in the United States and Japan,” Medicine, vol. 83, no. 3, pp. 193–207, 2004.
[7]
D. Cella, K. Webster, and J. Beaumont, The FACIT-Fatigue Scale: Description, Reliability and Validity, Center on Outcomes, Research and Education, Evanston, Ill, USA, 2003.
[8]
J. Torres, B. De Vroey, M.-P. No?l, B. Notteghem, and J.-F. Colombel, “Recurrent small bowel ischemia in a patient with paroxysmal nocturnal hemoglobinuria,” Nature Reviews Gastroenterology and Hepatology, vol. 7, no. 7, pp. 410–414, 2010.
[9]
G. Meyers, I. Weitz, T. Lamy, et al., “Disease-related symptoms reported across a broad population of patients with paroxysmal nocturnal hemoglobinuria,” Blood (ASH Annual Meeting Abstracts), vol. 110, no. 11, p. 3683, 2007.
[10]
P. Muus, J. Szer, H. Schrezenmeier, et al., “Evaluation of paroxysmal nocturnal hemoglobinuria disease burden: the patient's perspective. A report from the International PNH Registry,” Blood, vol. 116, no. 21, abstract 1525, 2010.
[11]
J. Lee, J. Jun Ho, Y. Sung Soo, et al., “High prevalence and mortality associated with thromboembolism in Asian patients with paroxysmal nocturnal hemoglobinuria (PNH),” Haematologica, vol. 95, no. 205, abstract 0505, supplement 2, pp. 205–206, 2010.
[12]
M. T. Gladwin, J. H. Crawford, and R. P. Patel, “The biochemistry of nitric oxide, nitrite, and hemoglobin: role in blood flow regulation,” Free Radical Biology and Medicine, vol. 36, no. 6, pp. 707–717, 2004.
[13]
R. P. Rother, L. Bell, P. Hillmen, and M. T. Gladwin, “The clinical sequelae of intravascular hemolysis and extracellular plasma hemoglobin: a novel mechanism of human disease,” Journal of the American Medical Association, vol. 293, no. 13, pp. 1653–1662, 2005.
[14]
A. Sch?fer, F. Wiesmann, S. Neubauer, M. Eigenthaler, J. Bauersachs, and K. M. Channon, “Rapid regulation of platelet activation in vivo by nitric oxide,” Circulation, vol. 109, no. 15, pp. 1819–1822, 2004.
[15]
K. I. Ataga, “Hypercoagulability and thrombotic complications in hemolytic anemias,” Haematologica, vol. 94, no. 11, pp. 1481–1484, 2009.
[16]
I. C. Weitz, P. Razavi, L. Rochanda et al., “Eculizumab therapy results in rapid and sustained decreases in markers of thrombin generation and inflammation in patients with PNH independent of its effects on hemolysis and microparticle formation,” Thrombosis Research, vol. 130, no. 2, pp. 361–368, 2012.
[17]
D. Helley, R. P. de Latour, R. Porcher et al., “Evaluation of hemostasis and endothelial function in patients with paroxysmal nocturnal hemoglobinuria receiving eculizumab,” Haematologica, vol. 95, no. 4, pp. 574–581, 2010.
[18]
M. J. Borowitz, F. E. Craig, J. A. DiGiuseppe et al., “Guidelines for the diagnosis and monitoring of paroxysmal nocturnal hemoglobinuria and related disorders by flow cytometry,” Cytometry B, vol. 78, no. 4, pp. 211–230, 2010.